This trial is evaluating whether Recombinant Human Papillomavirus Nonavalent Vaccine will improve 1 primary outcome and 4 secondary outcomes in patients with Allogeneic Hematopoietic Stem Cell Transplant Recipient. Measurement will happen over the course of Up to 3 days post-intervention.
This trial requires 48 total participants across 1 different treatment group
This trial involves a single treatment. Recombinant Human Papillomavirus Nonavalent Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"Hematologic malignancies continue to show an extremely high rate of allogeneic hematopoietic stem cell transplantation after autologous or nonreactive allo-HSCT. The rate of cure is still high. The treatment of these patients remains difficult even today due to their high morbidity and mortality." - Anonymous Online Contributor
"Although long-term survival rates are low, initial curative treatment is possible for hematologic neoplasms such as myelodysplastic syndrome, acute myelogenous leukemia, and acute lymphoblastic leukemia. In addition to intensive chemotherapy, bone marrow or hematopoietic stem cell transplantation may be helpful in some patients." - Anonymous Online Contributor
"Treatment choices are highly influenced by prognostic factors and the extent of disease. Given the high use of aggressive therapies, there is a clear need for a careful assessment of therapeutic options and their role in the management of patients with hematological malignancies, which are associated with high rates of adverse events." - Anonymous Online Contributor
"These signs and symptoms, if present, suggest an underlying hematologic neoplasm. An elevated white count, fatigue, swollen lymph nodes, anemia, and low platelet count are common. The most common underlying hematologic malignancy is acute myeloid leukemia, followed by chronic myelomonocytic leukemia, chronic myelocytic leukemia, lymphoproliferative disorder, and myelofibrosis." - Anonymous Online Contributor
"Myelodysplastic syndromes, B-cell malignancies, and acute myelogenous leukemias and lymphomas are the most common hematologic malignancies in the United States. Of the 4727 individuals with a diagnosis of first-time myelodysplastic syndrome, 12% were black." - Anonymous Online Contributor
"Many hematologic neoplasms are associated with infectious and noninfectious disorders, which indicates their pathogenesis. Although infectious and noninfectious causes are associated with a range of solid and hematological neoplasms, in many cases it is possible to prove the etiologic role of an infectious or noninfectious cause." - Anonymous Online Contributor
"The 5-year relative survival rate for all hematologic malignancies is approximately 86%. Although specific survival rates differ by tumor type, the mean survival time for an individual hematologic malignancy is approximately 9.3 ± 1.9 months." - Anonymous Online Contributor
"Findings from a recent study provides the first evidence that a single vaccine dose of the 11 different papillomavirus types included in the FDA-approved Gardasil/Cervarix combination vaccine generates broad humoral immunity to all 11 types and elicits immunity to subsequent infection with the same and disparate types. The potential of this vaccine to provide cross immunity is a major advance in the control of high-risk HPV, especially important for reducing the development and transmission of anal cancer." - Anonymous Online Contributor
"The rate of side effects associated with vaccination is high and similar across studies. Most were local in nature, and transient. Few side effects were associated with vaccination. The safety of the vaccine has been reported across studies and in different geographic areas in different pediatric populations. As such, the potential health of future generations of children must weigh the merits and risks of vaccination against the potential harms of not immunizing children." - Anonymous Online Contributor
"According to our results, noninfected HPV16-11 vaccines may not inhibit HPV16 vaccine-induced anticancer immunity. We postulate that a noninfected HPV16-11 vaccine may prevent the development of HPV vaccine-induced anticancer immunity, because there is no immune response to noninfected HPV16-11 vaccines." - Anonymous Online Contributor
"Overall, HPV vaccines were effective both as preventive of disease and as immunotherapies for treatment of disease. These data provide further support for the long-term safety and persistence of viral immunity elicited by the rHPV vaccines used in this program. These data also suggest that the magnitude and duration of immunity elicited by the vaccines used herein are likely not sufficient for the development of an effective immune response in patients with advanced-stage disease." - Anonymous Online Contributor
"If the clinical trial is not tailored to meet the needs of the individual, there is a high chance that the investigator's efforts will be wasted. Inclusion criteria need to be developed and validated within the scientific community to facilitate and drive trial design. Clinical trials should always be the first consideration." - Anonymous Online Contributor